The CDC's Respiratory Illnesses Data Channel, updated June 12, 2026, delivered a statement that deserves more attention than it has received: human metapneumovirus (HMPV) is elevated nationally. This surveillance flag appears alongside the parainfluenza (PIV) elevation that has been generating croup-related coverage this week — but HMPV is a distinct pathogen with a different epidemiology, different high-risk populations, and a clinical underdiagnosis problem that is arguably more serious than almost any other respiratory virus in circulation.
Human metapneumovirus was first identified in 2001, making it one of the newer major respiratory pathogens. Despite this, it circulates every year without fail and has established itself as one of the most clinically significant respiratory viruses in human medicine. A major epidemiological study of HMPV published in May 2026 estimated that HMPV is responsible for more than 200,000 hospitalizations in the United States every year — more than influenza B in most seasons, and approaching the hospitalization burden of RSV. Despite this, HMPV is tested for in a small fraction of the patients who likely have it, because most clinical respiratory testing panels — even in emergency departments — include influenza, RSV, and SARS-CoV-2 but frequently do not include HMPV unless specifically requested.
The practical consequence is that a significant proportion of patients admitted to hospitals with "non-specific viral respiratory illness" or "influenza-negative pneumonia" are almost certainly infected with HMPV, and neither they nor their physicians know it.
Who Gets the Sickest From HMPV
HMPV infects people of all ages — studies show that essentially all children have been infected by age 5 — and causes a range of illness from mild cold-like symptoms (runny nose, cough, sore throat, fever) to severe lower respiratory tract disease including bronchitis, bronchiolitis, and pneumonia. In healthy young adults, HMPV rarely causes severe disease. The populations at greatest risk for serious illness are those who are immunocompromised, older adults over 65, infants, and people with underlying cardiopulmonary conditions.
In immunocompromised patients — particularly hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant recipients, and patients receiving chemotherapy or biologic therapies — HMPV is responsible for a disproportionate share of the most dangerous and potentially fatal respiratory infections. The virus causes lower respiratory tract disease in this population at rates substantially higher than in healthy adults, and progression from upper respiratory illness to pneumonia can occur rapidly. Mortality from HMPV lower respiratory tract disease in HSCT recipients has been reported at 20 to 50 percent in some series.
For adults over 65, HMPV is the third most common cause of pneumonia in this age group, after influenza and RSV, with an annual hospitalization rate of approximately 25 to 30 per 100,000 among those over 75. HMPV pneumonia in older adults often requires prolonged hospitalization and can lead to respiratory failure requiring mechanical ventilation.
The Underdiagnosis Problem
There is no FDA-approved specific treatment for HMPV, and there is no vaccine — making the clinical management of HMPV pneumonia entirely supportive. But underdiagnosis matters even in the absence of a specific antiviral, for several important reasons.
First, diagnostic accuracy affects cohorting decisions in hospitals. Patients with HMPV placed in isolation with other HMPV-positive patients reduce the risk of cross-transmission of the virus to other vulnerable patients on the same unit. Patients incorrectly assumed to have influenza may receive oseltamivir (Tamiflu), which has no activity against HMPV — wasting a course of medication and leaving the patient without an accurate diagnosis.
Second, accurate HMPV diagnosis informs prognosis. HMPV pneumonia in a transplant recipient carries a mortality risk that should inform family conversations and goals-of-care discussions. When the diagnosis is "viral pneumonia, etiology unknown," those conversations are necessarily less precise.
For patients, families, and primary care physicians: any immunocompromised patient, transplant recipient, or adult over 65 who develops respiratory illness during June and July — the period of elevated HMPV activity — and who tests negative for influenza and RSV should have HMPV specifically requested as part of a respiratory PCR panel. This single test, added to most existing clinical PCR platforms at minimal incremental cost, can change management, isolation decisions, and prognostic conversations.
Frequently Asked Questions
Q: What is human metapneumovirus (HMPV)?
A: HMPV is a common respiratory virus first identified in 2001 that causes illness ranging from mild cold-like symptoms to severe pneumonia, bronchiolitis, and respiratory failure. It is related to RSV and is one of the most clinically significant respiratory pathogens in medicine.
Q: Why is HMPV being flagged as elevated nationally by the CDC right now?
A: CDC's Respiratory Illnesses Data Channel, updated June 12, 2026, listed HMPV among viruses elevated nationally — though declining. HMPV typically peaks in late winter and spring, making June elevation an extended active season.
Q: Who is at highest risk from HMPV?
A: Immunocompromised individuals (transplant recipients, chemotherapy patients), adults over 65, infants, and people with chronic cardiopulmonary disease. HMPV causes 200,000 US hospitalizations per year.
Q: Why is HMPV underdiagnosed?
A: Most routine respiratory pathogen panels in emergency departments and clinics test for influenza, RSV, and COVID-19 but not HMPV. Patients with "non-specific viral pneumonia" may have HMPV that is never identified.
Q: Is there a treatment or vaccine for HMPV?
A: No approved antiviral treatment or vaccine currently exists for HMPV. Management is supportive. Diagnostic accuracy improves cohorting, prognosis, and family communication.
